Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Pfizer (PFE - Analyst Report) recently entered into two deals. While one deal was signed with biopharma company Halozyme Therapeutics, Inc. (HALO - Snapshot Report), the second deal was signed with clinical intelligence company, Humedica.

Under the agreement with Halozyme, Pfizer will develop and commercialize products using its proprietary biologics in combination with Halozyme’s Enhanze technology. Enhanze, Halozyme's proprietary drug delivery platform, is based on the company's patented recombinant human hyaluronidase enzyme (rHuPH20).

Up to six targets will be developed and commercialized by Pfizer using Halozyme’s rHuPH20. Pfizer will initially pay $8 million including an upfront fee for exclusive licenses to two identified targets in the primary and specialty care settings. Besides this, Halozyme is entitled to receive payments based on the achievement of development, regulatory and sales milestones. Halozyme will also receive royalties on net sales of licensed products.

Under the second agreement, Pfizer and Humedica will work on combining clinical informatics and life science knowledge so as to gain a better understanding of the needs of patients and the effectiveness of treatments. This should help improve patient outcomes.

While Halozyme shares were up on the news regarding its agreement with Pfizer, we do not expect the Halozyme or the Humedica agreements to have any impact on Pfizer’s shares. We currently have a Neutral recommendation on both Pfizer and Halozyme. Both stocks carry a Zacks #3 Rank (Hold). We expect near-term earnings at Pfizer to be driven by cost cutting efforts and share repurchases. Longer-term growth will be dependent on the success of drug development.

Pharma stocks that currently look more attractive include companies like Allergan (AGN - Analyst Report) and Novo Nordisk (NVO - Analyst Report). Both companies carry a Zacks #2 Rank (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%